中西医联合治疗单纯疱疹性角膜炎的疗效观察

目的 :探讨单纯疱疹性角膜炎是中西医联合用药的治疗方法。方法 :本组 10 0例 ( 10 6只眼 )单纯疱疹性角膜炎患者应用抗病毒药物联合清热解毒中药的疗效观察。结果 :本组病例治疗后总有效率 82 .0 8%。结论 :中西医联合治疗措施是我们对单纯疱疹性角膜炎治疗的一项新的探讨。     

基质金属蛋白酶与肺癌转移的关系

基质金属蛋白酶(matrix metalloproteinases，MMPs)是一组锌离子依赖的蛋白水解酶，在ECM降解中起着重要作用。目前研究表明，MMPs活性异常不仅能促进肿瘤血管形成，还是人类多种肿瘤侵袭和转移的必要条件。本文就与肺癌侵袭和转移有关的MMPs研究作一综述。     

对诊断PADAM的血清游离睾酮界限值的初探

目的探寻诊断中老年男子部分雄激素缺乏综合征(PADAM)血清游离睾酮(FT)的界限值。方法根据60例45岁以上健康男性完成伊斯坦布尔症状量表(ISS)与视听性刺激(AVSS)时阴茎勃起监测结果进行分组,计算AVSS勃起功能正常组推算的游离睾酮(CFT)值的参考范围。结果AVSS勃起功能正常组CFT的中位数为0．37(0．20～0．52)nmol/L,异常组的中位数为0．25(0．12～0．40)nmol/L,z=2．25,P＜0．05,差别有显著性意义。两组性功能症状的差别也有极显著性意义(P＜0．01)。CFT的界限值是0．20nmol/L。结论研究用ISS和AVSS勃起功能正常对象的血清FT值,可为诊断PADAM建立界限值。     

妇幼卫生专业毕业生的追踪调查

20 0 2年 9～ 1 2月对中山大学公共卫生学院妇幼卫生专业的毕业生及用人单位进行了信函追踪调查。结果表明 :总体而言 ,该系学生思想素质、业务水平、工作能力均较强 ,受到用人单位的一致好评。该系学生保健服务能力是强项 ,体现了“以保健为中心”的办学思想。但同时也发现妇幼系的培养模式、课程设置、教学方法均存在一定问题 ,最突出的是临床动手能力较差 ,其次为社区工作能力、组织管理能力、社交能力相对不足 ,创新能力较差 ,所以教学改革势在必行     

经直肠超声引导下经会阴125I粒子永久植入治疗前列腺癌的初步经验

目的探讨经直肠超声引导下经会阴125I粒子永久植入治疗前列腺癌的疗效和并发症。方法本组前列腺癌患者5例。年龄61￣83岁,平均70.4岁。临床分期T2bN0M0者2例,T3aN0M0者3例。Gleason评分6分者2例,7分者1例,8分者2例。术前前列腺特异性抗原(PSA)4.5￣17.5ng/ml。T3a期患者植入治疗前先行内分泌治疗。术前制定治疗计划,经直肠超声引导下经会阴125I粒子永久植入操作。术后观察PSA水平变化,连续3次PSA升高即为生化复发,观察术后尿路和直肠并发症发生情况。结果5例患者均术后恢复顺利。术后随访18个月,PSA均明显下降,PSA为0.1ng/ml者3例,0.01ng/ml者1例,0.04ng/m1者1例。5例患者术后均出现不同程度的尿路刺激症状,但6个月后逐渐好转。4例术后出现排便次数增多,术后3个月均好转。未发现尿失禁、直肠溃疡等并发症。结论经直肠超声引导下经会阴125I粒子永久植入治疗前列腺癌的疗效确切,创伤较小。     

重氮乳胶反向凝集试验与乳凝试验在血吸虫病临床诊断中的应用研究

本文应用日本血吸虫虫卵单克隆抗体及虫卵可溶性抗原，分别致敏新型免疫微球载体重氮基聚苯乙烯乳胶，制备出血吸虫反向乳凝试剂与乳凝试剂，并用于检测血吸虫病患者血清标本中的相应抗原和相应抗体，以此试验检测１９７份急慢性血吸虫病患者血清标本。结果反向乳凝试剂检出率为９０．４％，乳凝试剂检出率为９５．２％，均高于反向间接血凝法的８５．０％。反向乳凝试验与乳凝试验联合应用，既可早期诊断，又可判断疗效。试验采用玻片凝集法，３ｍｉｎ内即出结果，方法敏感．特异、简便和快速。     

Inhibitory effect of glycyrrhiza uralensis fish and chelidonium majus L on gastrocarcinogenesis induced by N-methyl-N′-nitron-N-nitrosoguanidine

In order to investigate the antagonistic effect of Glycyrrhiza Uralensis Fish (GUF) and Chelidonium maJus L (CML) on gastrccarcinogenesis induced by MNNG in Wastar rats, we treated the rats with MNNG alone (group 1) and with MNNG plus GUF and CML (group 2 and 3) respectively. The incidence of infiltrating adenocarcinoma of the glandular stomach and duodenum in group 2 was significantly lower than that in group 1 (26.7% vs. 67.8%). The differentiation and aggressivenees of carcinomas occured in group 2 were much better and mild than those in group 1. Present study also demonstrated that the inhibitory effect of CML on proliferation of human stomach carcinoma cell line MGC-803 was very remarkable; in addition, GUF and CML were able to antagonise the mutagenic activation of MNNG. These results suggest that GUF and CML may be empoyed in prevention of gastric carcinoma.     

Phase II study of 10-ethyl-10-deaza-aminopterin (10-EdAM; CGP 30 694) for stage IIIB or IV non-small cell lung cancer

Summary Thirty-one patients with stage IIIB or IV non-small cell lung cancer (NSCLC) were treated with intravenous 10-EdAM on a weekly basis. The starting dose was 80 mg/m², with subsequent doses adjusted depending on evidence of toxicity. There were 20 men and 11 women with a median age of 58 years (range, 33–75). Response was evaluated in 30 patients, 5 with evaluable but not measurable tumors and 25 with measurable indicator lesions. There were no complete remissions; 3 patients achieved partial remission. Nine patients had a minor response, 6 showed no change, and 12 had progressive disease. Median survival for all 31 patients was 43 weeks (range, 12–65+). During the first 3-week period, the 10-EdAM dose was reduced or withheld in 19 patients (because of stomatitis in 12, SGPT elevation in 3, skin rash in 2, and granulocytopenia in 2), escalated in 11 patients, and unchanged in 1 patient. A mean of 34–88 mg/m²of 10-EdAM (median, 50) was given per week during the first 5-week period. Myelotoxicity was infrequent and there was no significant nephrotoxicity. Considering the modest side effects of this treatment and the conservative dose-modification schedule which mandated substantial dose reductions, we conclude that 10-EdAM is a promising antitumor agent for NSCLC.